Clinical Trial Update: A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003) [Phase 1]

View source ↗

Summary

Phase 1 trial of islatravir (MK-8591) in ART-naive HIV-1 infected participants has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hiv-1

Drugs mentioned

• Islatravir (MK-8591) (islatravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 | Phase 1 | Status: COMPLETED | Results posted: 2018-12-03